louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT05521035: Risk and Incidence of Aortic Graft and Endograft Infection With BSI
Official title: Risk and Incidence of Aortic Graft and Endograft Infection in Patients With Bloodstream Infection, a Population Based Study in South Sweden
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Aortic Infections and Inflammations
Lead sponsor: Lund University
Sponsor class: OTHER
First posted: 2022-08-30
Enrollment: 2000
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: All patients with previous aortic vascular graft or endograft surgery in Skåne, Halland, Kronoberg and Blekinge between the years 2010-2021.

Brief summary: What is the risk of aortic vascular graft and endograft infection in patients with aortic vascular graft/endograft and bloodstream infection?

Detailed description: All patients with previous aortic vascular graft and endograft surgery between years 2010 and 2021 in four regions of south Sweden (Skåne, Halland, Kronoberg and Blekinge) will be included in the study. These patients will be evaluated for bloodstream infection (BSI) or not. For all patients with BSI, the risk of aortic vascular graft and endograft infection will be investigated. Aortic vascular graft and endograft infection will be determined by usage of the MAGIC-criteria.

Risk factors for developing aortic vascular graft and endograft infection will be investigated, and if possible used to construct a risk score. This risk score could be used by clinicians to determine if bacteremic patients with aortic vascular grafts or endografts should be evaluated for aortic vascular graft and endograft infection.

Eligibility criteria: Inclusion Criteria:

Previous aortic vascular graft or endograft infection with bloodstream infection.

Exclusion Criteria:

-

Primary outcomes:
measure: Aortic vascular graft or endograft infection
timeFrame: At least 1 year follow-up
Secondary outcomes:
Other outcomes:
Locations:
city: Helsingborg
country: Sweden
facility: Helsingborgs lasarett
Study officials:
affiliation: Lund University
name: Oskar Ljungquist
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03892135: Representation and Medication Use in Juvenile Idiopathic Arthritis
Official title: Representation and Medication Use in Juvenile Idiopathic Arthritis - RUMAJI
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Juvenile Idiopathic Arthritis
Keywords: Role of parents, children and physician
Qualitative
Interview
Juvenile idiopathic arthritis
Adherence
mechanisms of adherence in juvenile idiopathic arthritis
Lead sponsor: University Hospital, Montpellier
Sponsor class: OTHER
Collaborators: name: Research department, unknowns, Strategic & innovation consulting, Paris (anthropologists)
name: NORDIC pharma (funding)
First posted: 2019-03-27
Enrollment: 36
Sex: ALL
Minimum age (years): 1
Maximum age (years): 17
Standard ages: CHILD
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Children with JIA and their parents

Brief summary: According to the International League of Associations for Rheumatology classification, Juvenile Idiopathic Arthritis (JIA) comprises a heterogeneous group of arthritis of unknown cause and with onset before 16 years of age, characterized by joint inflammation lasting for 6 or more weeks. Few studies exist regarding the care experience of children affected by this rheumatic condition. On the other hand, methotrexate and biologics constitute the primary treatment for children with JIA. As with adults undergoing the same treatment, adherence is critical. Difficulties for children to take the drugs have been reported. Notwithstanding, if adherence promotion in pediatric chronic conditions has been the subject of recommendations with regard to care management, the investigators lack information to understand the grounds for adherence specifically in JIA. In order to understand and decipher the parent-child adherence mechanisms and practices, the RUMAJI study will be conducted. Indeed, improving the relational approach between children and their caregivers as well as unrestricted drug adherence involves researching and understanding how appropriation of the disease and treatment could be achieved.


Eligibility criteria: Inclusion criteria:

* all JIA forms
* all treatment type (NSAIDs, MTX, bDMARDs)

Exclusion criteria:

- none

Primary outcomes:
measure: Interview with parents
timeFrame: 1 day
Secondary outcomes:
measure: Interview with children
timeFrame: 1 day
measure: Interview with physicians
timeFrame: 1 day
Other outcomes:
Locations:
city: Montpellier
country: France
facility: Uhmontpellier
Study officials:
affiliation: University Hospital, Montpellier
name: Jean-David COHEN, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04448535: Effects of Ginkgo (Gingko Biloba) on Retinal and Choroidal Ocular Tissue
Official title: Effects of Ginkgo (Gingko Biloba) on Retinal and Choroidal Ocular Tissue
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Healthy
Lead sponsor: State University of New York College of Optometry
Sponsor class: OTHER
First posted: 2020-06-26
Enrollment: 20
Sex: ALL
Minimum age (years): 20
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: BASIC_SCIENCE

Brief summary: The purpose of this study is to understand the effect of Ginkgo Biloba oral supplements on retinal and choroidal ocular tissue.

Detailed description: The study objectives are to:

1. assess the changes from pre- to post- oral supplementation on retinal and choroidal thickness and blood flow, retinal oxygen saturation, ocular perfusion pressure, and retinal function

Eligibility criteria: Inclusion Criteria:

* Aged between 20 - 55 years, inclusive
* Good general and ocular health
* Corrected visual acuity of 20/40 or better
* No gingko biloba supplementation within the last 3 months

Exclusion Criteria:

* All significant ocular and any systemic disorders considered likely to affect the systemic or ocular vasculature
* History of ocular surgery, including refractive surgery
* Use of ocular medications
* Conditions where ginkgo supplementation is contraindicated
* Any eye or systemic disease that affect vision or refractive error
* Current smokers
* Subjects who are pregnant, breastfeeding, or planning conception

Primary outcomes:
measure: ocular blood flow
timeFrame: 4 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: New York
country: United States
facility: SUNY College of Optometry
state: New York
Study officials:
References:
Clinical trial NCT02069535: An Open Trial to Assess the Tolerability of AVANZ® Cupressus Immunotherapy
Official title: An Open Trial to Assess the Tolerability of AVANZ® Cupressus Immunotherapy
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Allergic Rhinoconjunctivitis
Keywords: Cupressus arizonica
Lead sponsor: ALK-Abelló A/S
Sponsor class: INDUSTRY
First posted: 2014-02-24
Enrollment: 52
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This trial is an open, national, multi-centre trial. The main objective of this trial is to assess the tolerability of the up-dosing phase of AVANZ® Cupressus arizonica by measurement of related Adverse Events.

Detailed description: The main objective of this trial is to assess the tolerability of the up-dosing phase of AVANZ® Cupressus arizonica, the measurement rate is the frequency of patients with investigational medicinal product (IMP)-related adverse events (AEs) will be the primary endpoint.

Eligibility criteria: Inclusion Criteria:

* A documented clinically relevant history of Cupressus arizonica pollen induced allergic rhinoconjunctivitis with or without asthma for at least one year prior to trial entry.
* Positive Skin Prick Test (SPT) response to Cupressus arizonica pollen (wheal diameter ≥ 3 mm)

Exclusion Criteria:

* History of severe asthma exacerbation or emergency room visit or admission for asthma in the previous 12 months.
* Previous treatment with immunotherapy with Cupressus arizonica pollen extract within the last 5 years (initiation of subcutaneous immunotherapy is acceptable if treatment has been discontinued before reaching maintenance dose; for SLIT 3 months in the last 5 years is accepted).
* Ongoing treatment with any allergen-specific immunotherapy product.
* A history of anaphylaxis with cardiorespiratory symptoms (immunotherapy, exercise-induced, food allergy, drugs or an idiopathic reaction).
* A systemic disease affecting the immune system (e.g. insulin-dependent diabetes, autoimmune disease, immune complex disease, or immune deficiency disease whether acquired or not).

Primary outcomes:
measure: Frequency of patients with IMP-related AEs
timeFrame: 6 treatment weeks
Secondary outcomes:
measure: Frequency of patients with systemic reactions
timeFrame: 6 weeks of treatment
Other outcomes:
Locations:
city: Madrid
country: Spain
facility: Hospital Clinico Universitario San Carlos
Study officials:
affiliation: Hospital Clínico Universitario San Carlos, Madrid
name: Montserrat Fernández Rivas, PhD
role: STUDY_CHAIR
References:
Clinical trial NCT00647335: Genetics of Polycystic Ovary Syndrome
Official title: Population Genetics of Polycystic Ovary Syndrome
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: PCOS
Lead sponsor: University of Pennsylvania
Sponsor class: OTHER
Collaborators: name: University of Iowa
First posted: 2008-03-31
Enrollment: 189
Sex: FEMALE
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Women with a diagnosis of PCOS undergoing treatment at University of Pennsylvania and University of Iowa.

Brief summary: The purpose of this study is to look at genes (DNA) and how they affect health and disease. Genes are the instruction manual for the body. The genes you get from your parents decide what you look like and how your body behaves. They can also tell us a person's risk for certain diseases and how they will respond to treatment. We will collect a saliva sample for genetic research.

Detailed description: Polycystic ovary syndrome (PCOS) is a common endocrine disorder of women, characterized by elevated levels of male hormones, absent menstruation, infrequent or very light menstruation, and reduced ability to reproduce. Genetic factors likely contribute to the etiology of PCOS, but no genes have been identified with certainty. The findings from these studies will enhance our understanding of the genetics of PCOS, a major contributor to female infertility. Better knowledge of "PCOS genes" will also help in predicting responses to treatments for infertility, insulin resistance, and other aspects of the disease.

Women with PCOS may be eligible to participate in this study if they are between the ages of 18 and 50 and have two living biological parents who are also willing to participate. Study participation involves telephone screening and consent and home collection by subjects (probands) and their parents of sputum (saliva) in a provided container. Specimen containers and signed consent forms will be returned to the study site by mail.

The major goal of this research project, the identification of genes contributing to PCOS, will provide basic understanding of the genotype-phenotype relationships that contribute to features of PCOS. Knowledge of "PCOS genes" would assist physicians in predicting and assessing responses to interventions that promote fertility, improve insulin sensitivity, and treat other aspects of the disease.

Eligibility criteria: Inclusion Criteria:

* Diagnosis of PCOS
* Both biological parents alive
* Yes to both answers and parents willing to participate

Exclusion Criteria:

* Healthy women

Primary outcomes:
measure: PCOS gene identification.
timeFrame: December 2010
Secondary outcomes:
Other outcomes:
Locations:
city: Philadelphia
country: United States
facility: University of Pennsylvania
state: Pennsylvania
Study officials:
affiliation: University of Pennsylvania
name: Anuja Dokras-Jagasia, MD, PhD
role: PRINCIPAL_INVESTIGATOR
affiliation: University of Iowa
name: Brad V Voorhis, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00109135: A Study to Investigate a Research Drug as an Aid for Smoking Cessation in Chronic Cigarette Smokers (0364-007)
Official title: A Double-Blind, Multicenter, Randomized, Titrated-Dose, Placebo-Controlled, Study of MK0364 (4 mg to 8 mg) in Chronic Cigarette Smokers as an Aid for Smoking Cessation
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Smoking
Lead sponsor: Merck Sharp & Dohme LLC
Sponsor class: INDUSTRY
First posted: 2005-04-25
Enrollment: 300
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to evaluate the safety and tolerability of an investigational drug that may help individuals to stop smoking.


Eligibility criteria: Inclusion Criteria:

* Smoking greater than/equal to 10 cigarettes/day for at least 1 year
* Laboratory tests that meet the criteria of the study
* In overall good health as determined by the investigator

Exclusion Criteria:

* Psychiatric diagnoses
* Certain cancers
* Patients who use nicotine replacement therapy
* Patients on a diet regimen

Primary outcomes:
measure: Quitting smoking after 8 weeks of treatment by measuring lab values and expired breath CO levels
timeFrame: after 8 weeks of treatment
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
name: Medical Monitor
role: STUDY_DIRECTOR
References:
citation: Morrison MF, Ceesay P, Gantz I, Kaufman KD, Lines CR. Randomized, controlled, double-blind trial of taranabant for smoking cessation. Psychopharmacology (Berl). 2010 Apr;209(3):245-53. doi: 10.1007/s00213-010-1790-2. Epub 2010 Feb 27.
Clinical trial NCT05686135: 90Second IBD for the Improvement of Self Efficacy and Quality of Life in Inflammatory Bowel Disease Patients
Official title: 90Second IBD for the Improvement of Self Efficacy and Quality of Life in Inflammatory Bowel Disease Patients
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: NA
Conditions: IBD
Crohn Disease
Ulcerative Colitis
Lead sponsor: Nova Scotia Health Authority
Sponsor class: OTHER
Collaborators: name: 90 Second Health
name: Takeda
First posted: 2023-01-17
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: OTHER

Brief summary: Patients with Inflammatory Bowel Disease (IBD) have poorer quality of life than healthy people. Despite the high prevalence of psychological issues and its profound influence on quality of life, most IBD patients have limited access to mental health support. As well, many may decline support if it is offered because mental health is often not thought of as part of IBD care. Patients may be able to access cognitive behavioural therapy (CBT) through a psychologist, however this intervention is costly and requires considerable commitment on the part of person with IBD. There is a need for new methods of reaching IBD patients to provide information on their psychological needs, and normalize the psychological effects of IBD. These new methods should integrate medical issues with psychosocial issues while being effective, scalable, and low cost to the health care system. 90SecondIBD is a novel way of delivering health information about IBD using Persuasive Design technology embedded in a planned behavior model. This project will investigate the effect of the intervention "90SecondIBD", a weekly online health letter, on IBD patients' quality of life and self efficacy. Regression modelling will be performed to explore the ability of clinical and demographic factors to predict quality of life and self efficacy scores following receipt of 90SecondIBD educational health letters weekly for 6 months and 12 months.


Eligibility criteria: Inclusion Criteria:

* Adult, resident of Canada, diagnosis of IBD, access to a computer or cell phone

Exclusion Criteria:

* N/A

Primary outcomes:
measure: IBD Specific Quality of life
timeFrame: month 0 (baseline)
measure: IBD Specific Quality of life
timeFrame: month 6
measure: IBD Specific Quality of life
timeFrame: month 12
measure: Self Efficacy
timeFrame: month 0 (baseline)
measure: Self Efficacy
timeFrame: month 6
measure: Self Efficacy
timeFrame: month 12
Secondary outcomes:
measure: Participant Satisfaction with 90SecondIBD
timeFrame: month 6
measure: Participant Satisfaction with 90SecondIBD
timeFrame: month 12
Other outcomes:
Locations:
city: Halifax
country: Canada
facility: QEII Health Sciences Centre
state: N.S.
Study officials:
References:
Clinical trial NCT04778735: Investigation of Mortality, Morbidity and Risk Factors After Pediatric Liver Transplantation
Official title: Investigation of Mortality, Morbidity and Risk Factors After Pediatric Liver Transplantation: A Retrospective Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Liver Transplantation
Liver Diseases
Biliary Atresia
Morbidity;Infant
Mortality
Lead sponsor: Memorial Bahçelievler Hospital
Sponsor class: OTHER
First posted: 2021-03-03
Enrollment: 207
Sex: ALL
Minimum age (years): 0
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The Department of Organ Transplantation in Memorial Hospitals has started Pediatric Liver Transplantation Program in 2016. As of the end of 2020, we have performed 169 pediatric liver transplantation. The aim of this study is to investigate the overall mortality, morbidity and risk factors for adverse outcomes in pediatric liver transplantation. The patients' records will be retrospectively scanned and the data will be gathered.


Eligibility criteria: Inclusion Criteria:

* Pediatric patients with liver transplantation (\<18 years)

Exclusion Criteria:

* Patients with incomplete medical records will be excluded

Primary outcomes:
measure: Survival
timeFrame: 1 minutes
Secondary outcomes:
measure: Perioperative informations
timeFrame: 5 minutes
measure: Blood Tests
timeFrame: 15 minutes
measure: Postoperative Complications
timeFrame: 5 minutes
measure: Postoperative informations
timeFrame: 10 minutes
Other outcomes:
Locations:
city: Istanbul
country: Turkey
facility: Memorial Bahçelievler Hospital
Study officials:
References:
Clinical trial NCT04068935: Buddy Taping Compared to Splint Immobilization for Displaced Paediatric Finger Fractures
Official title: Buddy Taping Compared to Splint Immobilizations for Reduced Paediatric Finger Fractures
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Fracture Finger
Lead sponsor: University Children's Hospital, Zurich
Sponsor class: OTHER
First posted: 2019-08-28
Enrollment: 50
Sex: ALL
Minimum age (years): 4
Maximum age (years): 16
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Fracture immobilization with Buddy taping is not inferior to Splint immobilization for non-displaced extra-articular paediatric finger fractures. However, whether the same applies for reduced finger fractures is unclear.

Detailed description: Displaced fractures will be reduced in the paediatric ED by Emergency physicians. After fracture reduction, fracture immobilization will either be done with a Splint immobilization or a fingertaping. After 4 and 21 days, clinical and radiographic controls will take place at the Hand surgery outpatient clinic.

Eligibility criteria: Inclusion Criteria:

* extraarticular displaced finger fractures of the proximal or middle phalanges

Exclusion Criteria:

* fractures of the thumb
* fractures that are open, instable, pathologic or multifragmented
* multiple fractures of the Hand
* phalangeal neck fractures
* presentation later than 5 days after the injury

Primary outcomes:
measure: secondary fracture displacement
timeFrame: 5 and 21 days after fracture reduction
Secondary outcomes:
measure: Patient comfort
timeFrame: 5 and 21 days after fracture reduction
measure: Need for analgesic medication
timeFrame: 5 and 21 days after fracture reduction
measure: total range of Motion
timeFrame: 6 month after fracture reduction
Other outcomes:
Locations:
city: Zürich
country: Switzerland
facility: University Children's Hospital Zurich
Study officials:
affiliation: University Children's Hospital, Zurich
name: Michelle Seiler, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03338335: Ethnic Differences and the Ischemia/Bleeding Risk of DAPT Duration
Official title: Ethnic Differences in Ischemia/Bleeding Risk Tradeoff During Antiplatelet Therapy After Drug-eluting Stent Implantation
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Coronary Artery Disease
Percutaneous Coronary Intervention
Dual Antiplatelet Therapy
Lead sponsor: Seoul National University Hospital
Sponsor class: OTHER
First posted: 2017-11-09
Enrollment: 16000
Sex: ALL
Minimum age (years): 19
Maximum age (years): 100
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: OTHER
Sampling method: NON_PROBABILITY_SAMPLE
Study population: individual participant data (IPD) meta-analysis of randomized controlled trials designed to investigate the efficacy and safety of shorter duration of DAPT with a longer duration DAPT in patients with ischemic heart diseases.

Brief summary: this study is an individual patient level meta-analysis of randomized clinical trials, to evaluate the influence of ethnicity, to study whether the relative tradeoff between ischemia and bleeding is distinct by ethnicity.


Eligibility criteria: Inclusion Criteria:

* patients enrolled in previous RCTs related to the duration of dural antiplatelet agent therapy

Primary outcomes:
measure: primary ischemic endpoint
timeFrame: 2 years
measure: primary bleeding endpoints
timeFrame: 2 years
Secondary outcomes:
measure: all-cause death
timeFrame: 2 years
measure: cardiac death
timeFrame: 2 years
measure: non-cardiac death
timeFrame: 2 years
measure: any myocardial infarction
timeFrame: 2 years
measure: any stroke
timeFrame: 2 years
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Seoul National University Hospital
Study officials:
References:
citation: Kang J, Park KW, Palmerini T, Stone GW, Lee MS, Colombo A, Chieffo A, Feres F, Abizaid A, Bhatt DL, Valgimigli M, Hong MK, Jang Y, Gilard M, Morice MC, Park DW, Park SJ, Jeong YH, Park J, Koo BK, Kim HS. Racial Differences in Ischaemia/Bleeding Risk Trade-Off during Anti-Platelet Therapy: Individual Patient Level Landmark Meta-Analysis from Seven RCTs. Thromb Haemost. 2019 Jan;119(1):149-162. doi: 10.1055/s-0038-1676545. Epub 2018 Dec 31.